Zicam Sales Up, Matrixx Cuts Loss With Legal Expenses Down More Than Half
This article was originally published in The Tan Sheet
Executive Summary
High sales of Matrixx Initiatives' Zicam line in an out-of-season quarter helped the OTC manufacturer increase cold and cough product sales, the firm said